Table 3 (abstract P414).
See text for description
| Survivor (n = 19) | Non survivor (n = 23) | ||
|---|---|---|---|
| 3 Months previous hospitalization | 2/19 (10.5%) | 9/23 (39,1%) | P = 0.054 |
| Steroids use | 3/19 (15.8%) | 14/23 (60.9%) | P = 0.024 |
| Septic shock | 11/19 (57.9%) | 15/23 (65.2%) | P = 0.045 |
| SOFA (day 1) | 8.65 ± 3.37 | 11.9 ± 3.37 | P = 0.015 |
| SAPS II (day 1) | 57.58 ± 17.70 | 67.59 ± 20.99 | P = 0.034 |
| Charlson Score | 3.05 ± 1.87 | 4.00 ± 1.87 | Ns |
| Optimal empirical therapy | 17/19 (89.5%) | 20/23 (87%) | Ns |
| Previous carbapenems therapy | 2/19 (10.5%) | 9/23 (39.1%) | P = 0.081 |
| Oral gentamicin decontamination | 2/19 (21.1%) | 0/23 (0%) | P = 0.093 |
| Gentamicin therapy | 6/14 (42.9%) | 1/23 (4.3%) | P = 0.023 |
| Fosfomycin therapy | 5/14 (35.7%) | 3/23 (13%) | P = 0.066 |
| Gentamicin associated with other antibiotics | 6/19 (31.6%) | 15/23 (4.3%) | P = 0.072 |
Legend : Clinical characteristics, therapy and outcomes of study population